We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead Sciences has maintained its dominant position in the HIV marketplace thanks to a new generation of safer triplet drugs but ViiV Healthcare revealed more Phase III results suggesting that a long-acting injectable doublet may be able to elbow out a s